[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Ardalan MR, Shoja MM: Multiple myeloma presented as acute interstitial nephritis and rheumatoid arthritis-like polyarthritis. Am J Hematol; 2007 Apr;82(4):309-13
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma presented as acute interstitial nephritis and rheumatoid arthritis-like polyarthritis.
  • Acute interstitial nephritis and rheumatoid arthritis (RA) or RA-like polyarthritis are among the very rare paraneoplastic manifestations of multiple myeloma (MM).
  • He later developed a symmetric distal polyarthritis with morning stiffness mimicking RA.
  • Diagnosis of MM was made and the patient received chemotherapy.
  • After four-course chemotherapy, the patient's articular manifestations resolved, urine monoclonal spike disappeared, and serum creatinine returned to a near normal level.
  • We hypothesize that in this case, immunologic hypersensitivity reactions to the light-chain molecules or other tumoral antigens deposited within the kidney or joint spaces, in the context of MM cytokine milieu may have resulted in this unusual presentation.
  • Ultimately, clinicians and pathologists should consider MM in the differential diagnosis of the acute interstitial nephritis and RA-like polyarthritis.
  • [MeSH-major] Acute Kidney Injury / etiology. Arthritis, Rheumatoid / etiology. Multiple Myeloma / diagnosis. Nephritis, Interstitial / etiology


2. Yaccoby S: Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma; 2010 Feb;51(2):213-20
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteoblastogenesis and tumor growth in myeloma.
  • Myeloma is associated with suppression of osteoblastogenesis, consequentially resulting in increased osteoclast activity and induction of typical osteolytic bone disease.
  • The molecular mechanisms by which myeloma cells suppress osteoblastogenesis and the consequences of increased osteoblast activity on myeloma cell growth have been partially delineated only recently.
  • Reduced osteoblastogenesis is a consequence of abnormal properties and impaired osteogenic potential of osteoprogenitor cells from myeloma patients and is also the result of production of multiple osteoblastogenesis inhibitors by myeloma cells and by microenvironmental cells within the myelomatous bone.
  • Nevertheless, novel osteoblast-activating agents (e.g. proteasome inhibitor bortezomib) are capable of inducing bone formation in myeloma animal models and clinically.
  • These agents induce increased osteoblast activity, often coupled with a concomitant reduction in osteoclastogenesis, that is strongly associated with reduced myeloma tumor burden.
  • In vitro, osteoblasts, in contrast to osteoclasts, attenuate the growth of myeloma cells from a large subset of patients; potential molecular mechanisms are discussed.
  • These studies suggest that myeloma cells suppress osteoblastogenesis to their advantage and that increased osteoblast activity is a promising approach to treat myeloma bone disease and simultaneously control myeloma development and progression.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2009 Aug;23(8):1515-27 [19357701.001]
  • [Cites] Blood. 2009 Aug 27;114(9):1803-12 [19597185.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2699-708 [19652203.001]
  • [Cites] J Cell Biochem. 2009 Nov 1;108(4):769-77 [19718659.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50259-72 [14523023.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2308-15 [14615378.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2016-23 [15026338.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1655-64 [15084698.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6122-7 [15067127.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7058-64 [15466200.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1891-7 [15385929.001]
  • [Cites] J Bone Joint Surg Br. 1989 Mar;71(2):288-90 [2925748.001]
  • [Cites] J Clin Invest. 1991 Jul;88(1):62-6 [2056131.001]
  • [Cites] Eur J Haematol. 1992 Oct;49(4):192-8 [1464362.001]
  • [Cites] Blood. 1995 Oct 15;86(8):3151-9 [7579410.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18961-5 [8702560.001]
  • [Cites] J Clin Invest. 1998 Jan 15;101(2):406-12 [9435313.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):274-82 [9664068.001]
  • [Cites] Blood. 1998 Oct 15;92(8):2908-13 [9763577.001]
  • [Cites] Leuk Lymphoma. 1999 Jan;32(3-4):249-56 [10037022.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1383-95 [15471951.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1104-10 [15690056.001]
  • [Cites] Dev Cell. 2005 May;8(5):751-64 [15866165.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):200-5 [15936724.001]
  • [Cites] J Nippon Med Sch. 2005 Jun;72(3):137-45 [16046829.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1407-14 [15878977.001]
  • [Cites] J Biol Chem. 2005 Sep 16;280(37):32468-79 [15994311.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3576-82 [10552969.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1219-30 [11283920.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11581-6 [11562486.001]
  • [Cites] Br J Haematol. 2002 Feb;116(2):278-90 [11841428.001]
  • [Cites] N Engl J Med. 2002 Feb 21;346(8):564-9 [11856795.001]
  • [Cites] J Clin Invest. 2002 Apr;109(8):1041-8 [11956241.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3688-95 [12032837.001]
  • [Cites] Glycobiology. 2002 Sep;12(9):107R-16R [12213783.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):207-14 [12538471.001]
  • [Cites] J Cell Biochem. 2003 May 15;89(2):401-26 [12704803.001]
  • [Cites] J Clin Invest. 2003 Jun;111(11):1771-82 [12782679.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11917-23 [13679583.001]
  • [Cites] Eur Cell Mater. 2003 Oct 6;6:12-21; discussion 21 [14562268.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2472-83 [15933061.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):71-3 [16173965.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3160-5 [16030194.001]
  • [Cites] Haematologica. 2006 Feb;91(2):192-9 [16461303.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1283-96 [16522681.001]
  • [Cites] J Cell Biochem. 2006 May 1;98(1):1-13 [16440324.001]
  • [Cites] Stem Cells. 2006 Apr;24(4):986-91 [16293576.001]
  • [Cites] Cell Metab. 2006 Aug;4(2):111-21 [16890539.001]
  • [Cites] Eur J Haematol. 2006 Sep;77(3):233-8 [16923110.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Sep;7(2):109-14 [17026821.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Br J Haematol. 2006 Dec;135(5):688-92 [17107351.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2106-11 [17068150.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3147-51 [17170129.001]
  • [Cites] Leukemia. 2007 May;21(5):1079-88 [17344918.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3024-30 [17138824.001]
  • [Cites] Blood. 2007 Jul 1;110(1):334-8 [17371942.001]
  • [Cites] Am J Hematol. 2007 Sep;82(9):831-3 [17546639.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2181-91 [17657224.001]
  • [Cites] Br J Haematol. 2007 Nov;139(3):434-8 [17910634.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2833-42 [18094333.001]
  • [Cites] Bone. 2008 Apr;42(4):669-80 [18294945.001]
  • [Cites] Cell. 2008 Apr 4;133(1):38-52 [18394988.001]
  • [Cites] J Clin Pathol. 2008 May;61(5):577-87 [18441154.001]
  • [Cites] Eur J Haematol. 2008 Jun;80(6):490-4 [18331598.001]
  • [Cites] Mol Cancer Res. 2008 May;6(5):785-94 [18505923.001]
  • [Cites] Blood. 2008 Jul 1;112(1):196-207 [18305214.001]
  • [Cites] Blood. 2008 Jul 1;112(1):159-68 [18436739.001]
  • [Cites] Blood. 2008 Jul 15;112(2):374-82 [18344425.001]
  • [Cites] J Bone Miner Res. 2008 Aug;23(8):1170-81 [18627264.001]
  • [Cites] Int J Med Sci. 2008;5(5):263-72 [18797510.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2473-9 [18798267.001]
  • [Cites] Am J Hematol. 2009 Jan;84(1):6-14 [18980173.001]
  • [Cites] Leukemia. 2009 Jan;23(1):10-24 [18843284.001]
  • [Cites] Blood. 2009 Jan 15;113(3):517-25 [18687985.001]
  • [Cites] J Bone Miner Res. 2009 Mar;24(3):425-36 [19016584.001]
  • [Cites] Leukemia. 2009 Mar;23(3):435-41 [19039321.001]
  • [Cites] Blood. 2009 Apr 30;113(18):4319-30 [19196662.001]
  • [Cites] Am J Hematol. 2009 May;84(5):268-72 [19296472.001]
  • [Cites] Blood. 2009 May 28;113(22):5412-7 [19179464.001]
  • [Cites] Blood. 2009 Jul 9;114(2):371-9 [19417213.001]
  • (PMID = 20038269.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093897-03; United States / NCI NIH HHS / CA / CA093897-04; United States / NCI NIH HHS / CA / CA-093897; United States / NCI NIH HHS / CA / R01 CA093897-01A1; United States / NCI NIH HHS / CA / CA093897-01A1; United States / NCI NIH HHS / CA / CA093897-02; United States / NCI NIH HHS / CA / R01 CA093897-06; United States / NCI NIH HHS / CA / R01 CA093897-04; United States / NCI NIH HHS / CA / R01 CA093897-06S1; United States / NCI NIH HHS / CA / CA093897-03; United States / NCI NIH HHS / CA / R01 CA093897-07; United States / NCI NIH HHS / CA / R01 CA093897-05A1; United States / NCI NIH HHS / CA / R01 CA093897-02; United States / NCI NIH HHS / CA / R01 CA093897
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  • [Number-of-references] 85
  • [Other-IDs] NLM/ NIHMS189226; NLM/ PMC2849287
  •  go-up   go-down


3. Willmott F, Agarwal N, Heath M, Stevens J, Chakravarti S: Plasma cell myeloma diagnosed in pregnancy. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell myeloma diagnosed in pregnancy.
  • Plasma cell myeloma (PCM) is an essentially incurable neoplastic disorder of terminally differentiated B cells.
  • The clinical picture is one of bone marrow failure, due to infiltration of the marrow by malignant plasma cells; renal failure due to damage to renal tubules by the excess light chains and pain due to lytic lesions of the bones.
  • [MeSH-major] Multiple Myeloma / diagnosis. Pregnancy Complications, Neoplastic / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Bone Marrow / pathology. Cesarean Section. Disease Progression. Female. Fetal Growth Retardation / diagnosis. Hematopoietic Stem Cell Transplantation. Humans. Infant, Newborn. Male. Neoplasm Staging. Pregnancy. Puerperal Disorders / diagnosis. Puerperal Disorders / drug therapy. Puerperal Disorders / pathology. Remission Induction

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2004 Jun;86-A(6):1284-8 [15173303.001]
  • [Cites] Blood. 1966 Jul;28(1):102-11 [5944257.001]
  • [Cites] Obstet Gynecol. 1968 Jun;31(6):811-20 [5742077.001]
  • [Cites] West Indian Med J. 1971 Jun;20(2):97-100 [5110487.001]
  • [Cites] Cancer. 1974 Oct;34(4):1018-22 [4417641.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jan;111(1):38-42 [3800603.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):513-5 [2304725.001]
  • [Cites] Obstet Gynecol. 1990 Mar;75(3 Pt 2):516-8 [2304726.001]
  • [Cites] Int J Gynaecol Obstet. 1991 Aug;35(4):341-2 [1682183.001]
  • [Cites] Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):217-9 [7847542.001]
  • [Cites] Leuk Res. 1997 Sep;21(9):885-8 [9393604.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Am J Clin Pathol. 2005 Jul;124(1):108-12 [15923168.001]
  • [Cites] J Obstet Gynaecol. 2006 Oct;26(7):693-5 [17071446.001]
  • [Cites] Nephrol Dial Transplant. 2007 Dec;22(12):3652-5 [17875572.001]
  • [Cites] Int J Gynaecol Obstet. 2008 Jan;100(1):89-90 [17825829.001]
  • [Cites] Ann Hematol. 2009 Feb;88(2):181-2 [18682949.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Dec 10;111(2):214-5 [14597255.001]
  • (PMID = 22791481.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3027817
  •  go-up   go-down


Advertisement
4. Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E: Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol; 2005 Aug 1;23(22):5217-23
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
  • PURPOSE: To assess the prevalence, time of onset, risk factors, and outcome of avascular necrosis (AVN) of bone in patients with multiple myeloma undergoing antineoplastic therapy.
  • PATIENTS AND METHODS: A total of 553 consecutive assessable patients were enrolled onto a treatment protocol consisting of dexamethasone-containing induction chemotherapy, autologous stem-cell transplantation, consolidation chemotherapy, and maintenance with interferon alfa.
  • RESULTS: With a median follow-up of 33 months (range, 5 to 114 months), AVN of the femoral head(s) developed in 49 patients (9%).
  • Median time to onset of AVN was 12 months (range, 2 to 41 months).
  • AVN-related pain and limited range of motion of the affected joint were present in only nine and four patients, respectively, and four patients underwent hip replacement because of AVN.
  • Fluorine-18 fluorodeoxyglucose positron emission tomography failed to detect abnormal uptake in the AVN-affected bones.
  • CONCLUSION: AVN is a rare and usually asymptomatic complication during myeloma therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Femur Head Necrosis / etiology. Femur Head Necrosis / pathology. Immunosuppressive Agents / therapeutic use. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Age Factors. Aged. Dexamethasone / administration & dosage. Female. Humans. Interferon-alpha / administration & dosage. Male. Middle Aged. Odds Ratio. Prevalence. Risk Factors. Sex Factors. Stem Cell Transplantation. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15955903.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Interferon-alpha; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


5. Clerc D, Fermand JP, Mariette X: Treatment of multiple myeloma. Joint Bone Spine; 2003 Jun;70(3):175-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of multiple myeloma.
  • Conventional chemotherapies are no longer the only treatment in multiple myelomatosis.
  • High-dose chemotherapy and autologous transplantation are not curative but do increase relapse-free survival time in young patients.
  • Thalidomide is efficacious in refractory and relapsing myeloma and its evaluation is going on.
  • Curative and preventive treatments of skeletal events, infections and anemia improve quality of life.
  • All together, these strategies imply therapeutic knowledge and choices but allow an about 5-year-long median survival time in modern studies.
  • Treatment options for myeloma now include, not only conventional chemotherapy regimens, but also novel symptomatic drugs and strategies that increase survival and/or quality of life, although they fail to provide a cure.
  • In parallel with this expansion of the treatment armamentarium, physicians must acquire the knowledge needed to select the best treatment for the individual patient.
  • After reviewing the rationale, effectiveness, and safety of each of these treatments, we will discuss the indications that we believe are legitimate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Medical Oncology / methods. Multiple Myeloma / drug therapy

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12814760.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 96
  •  go-up   go-down


6. Combe B: Thalidomide: new indications? Joint Bone Spine; 2001 Dec;68(6):582-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thalidomide, which was developed as a nonbarbiturate sedative agent, was taken off the market in 1961 after it was linked to a spate of major birth defects.
  • Gradually, thalidomide was reintroduced for the treatment of a few skin diseases including leprous erythema nodosum, severe mucosal ulcers (e.g., associated with HIV infection or Behçet's disease), lymphocytic skin infiltrations, cutaneous lupus erythematosus, and chronic graft-versus-host disease.
  • Recent reports of original pharmacological properties including modulation of cytokine production (mainly reduced TNF-alpha production) and inhibition of angiogenesis have led to the suggestion that thalidomide may be useful in some inflammatory and neoplastic conditions.
  • The anti-angiogenic effects of thalidomide may make this compound valuable as single-drug therapy or as an adjunct to chemotherapy in patients with cancer, particularly those with metastases or multiple myeloma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Neovascularization, Pathologic / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Humans. Multiple Myeloma / drug therapy. Neoplasm Metastasis / drug therapy. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / metabolism

  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11809002.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Angiogenesis Inhibitors; 0 / Tumor Necrosis Factor-alpha; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 44
  •  go-up   go-down


7. Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B, Hose D: Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene; 2009 Nov 5;28(44):3866-79
HAL archives ouvertes. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathogenesis of multiple myeloma is associated with an aberrant expression of pro-proliferative, pro-angiogenic and bone-metabolism-modifying factors by malignant plasma cells.
  • Given the frequently long time span from diagnosis of early-stage plasma cell dyscrasias to overt myeloma and the mostly low proliferation rate of malignant plasma cells, we hypothesize these to similarly express a novel class of inhibitory factors of potential prognostic relevance.
  • We assessed the expression of BMPs and their receptors by Affymetrix DNA microarrays (n=779) including CD138-purified primary myeloma cell samples (n=635) of previously untreated patients.
  • Its expression is significantly lower in proliferating myeloma cells, myeloma cell lines or plasmablasts.
  • BMP6 significantly inhibits the proliferation of myeloma cell lines, survival of primary myeloma cells and in vitro angiogenesis.
  • A high BMP6 expression in primary myeloma cell samples delineates significantly superior overall survival for patients undergoing high-dose chemotherapy independent of conventional prognostic factors (International Staging System (ISS) stage, beta(2) microglobulin).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Bone Morphogenetic Protein 6 / biosynthesis. Cell Proliferation. Gene Expression Regulation, Neoplastic. Multiple Myeloma / metabolism. Multiple Myeloma / mortality. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / mortality


8. Santiago FR, Del Mar Castellano García M, Montes JL, García MR, Fernández JM: Treatment of bone tumours by radiofrequency thermal ablation. Curr Rev Musculoskelet Med; 2009 Mar;2(1):43-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of bone tumours by radiofrequency thermal ablation.
  • Radiofrequency thermal ablation (RFTA) is considered the treatment of choice for osteoid osteomas, in which it has long been safely used.
  • RFTA ablation is also an option for the palliation of localized, painful osteolytic metastatic and myeloma lesions.
  • The reduction in pain improves the quality of life of patients with cancer, who often have multiple morbidities and a limited life expectancy.
  • In some cases, these patients are treated with RFTA because conventional therapies (surgery, radiotherapy, chemotherapy, etc.) have been exhausted.
  • In other cases, it is combined with conventional therapies or other percutaneous treatments, e.g., cementoplasty, offering faster pain relief and bone strengthening.
  • A multidisciplinary approach to the management of these patients is recommended to select the optimal treatment, including orthopaedic surgeons, neurosurgeons, medical and radiation oncologists and interventional radiologists.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2007 Apr;28(4):700-5 [17416824.001]
  • [Cites] J Vasc Interv Radiol. 2002 Oct;13(10):1047-50 [12397128.001]
  • [Cites] Skeletal Radiol. 2006 Jan;35(1):1-15 [16205922.001]
  • [Cites] Instr Course Lect. 2005;54:497-503 [15948474.001]
  • [Cites] J Vasc Interv Radiol. 2005 Jun;16(6):765-78 [15947040.001]
  • [Cites] Radiology. 2005 Jun;235(3):728-39 [15845798.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1218-25 [9508210.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1628-45 [9362430.001]
  • [Cites] Orthop Clin North Am. 1996 Jul;27(3):559-74 [8649737.001]
  • [Cites] Skeletal Radiol. 1993 Oct;22(7):485-500 [8272884.001]
  • [Cites] Radiology. 1992 Apr;183(1):29-33 [1549690.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):509-24 [1705581.001]
  • [Cites] Skeletal Radiol. 2002 Oct;31(10):597-602 [12324830.001]
  • [Cites] Pediatr Radiol. 2002 Aug;32(8):615-8 [12200642.001]
  • [Cites] Spine (Phila Pa 1976). 2002 Aug 1;27(15):E361-5 [12163737.001]
  • [Cites] Radiology. 2002 Jul;224(1):87-97 [12091666.001]
  • [Cites] Radiology. 2001 Nov;221(2):463-8 [11687691.001]
  • [Cites] J Vasc Interv Radiol. 2001 Sep;12(9):1021-32 [11535764.001]
  • [Cites] Skeletal Radiol. 2001 Apr;30(4):219-22 [11392296.001]
  • [Cites] J Bone Joint Surg Br. 2001 Apr;83(3):391-6 [11341426.001]
  • [Cites] Radiology. 2000 Dec;217(3):657-64 [11110925.001]
  • [Cites] J Bone Joint Surg Br. 2000 Nov;82(8):1125-8 [11132271.001]
  • [Cites] AJR Am J Roentgenol. 2000 Nov;175(5):1263-6 [11044019.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jun;190(6):1492-4 [18492897.001]
  • [Cites] Eur Radiol. 2007 Nov;17(11):3012-3 [17622538.001]
  • [Cites] AJR Am J Roentgenol. 2007 Sep;189(3):W146-9 [17715082.001]
  • [Cites] Eur J Radiol. 2007 Jul;63(1):63-7 [17482405.001]
  • [Cites] CMAJ. 1986 Oct 15;135(8):895-9 [3756721.001]
  • [Cites] J Vasc Interv Radiol. 2004 Jul;15(7):707-12 [15231884.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):300-6 [14722039.001]
  • [Cites] Radiology. 2003 Oct;229(1):171-5 [12944597.001]
  • [Cites] J Vasc Interv Radiol. 2003 Jun;14(6):773-7 [12817045.001]
  • [Cites] Arch Orthop Trauma Surg. 2003 Apr;123(2-3):86-90 [12721686.001]
  • [Cites] AJR Am J Roentgenol. 2003 Apr;180(4):1075-7 [12646458.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1633-42 [12438068.001]
  • [Cites] Eur Radiol. 2006 Apr;16(4):804-10 [16267666.001]
  • (PMID = 19468917.001).
  • [ISSN] 1935-973X
  • [Journal-full-title] Current reviews in musculoskeletal medicine
  • [ISO-abbreviation] Curr Rev Musculoskelet Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2684952
  •  go-up   go-down


9. Azaïs I, Brault R, Debiais F: New treatments for myeloma. Joint Bone Spine; 2010 Jan;77(1):20-6
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New treatments for myeloma.
  • The management of multiple myeloma has benefited substantially from the introduction of three new drugs, namely, the proteasome inhibitor bortezomib and the immunomodulators thalidomide and lenalidomide.
  • These drugs were initially shown to improve the outcome of advanced myeloma and were subsequently found to transform the treatment of patients with previously untreated myeloma.
  • Melphalan and prednisone combined with thalidomide or bortezomib is the new treatment of reference for patients who are elderly or ineligible for intensification.
  • The introduction of these new drugs into induction regimens, intensified conditioning regimens, and posttransplantation regimens may improve overall survival among young patients by increasing the rate and quality of the treatment responses.
  • Although myeloma remains incurable, prolonged survival is now a reasonable objective.
  • [MeSH-major] Multiple Myeloma / drug therapy. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use
  • [MeSH-minor] Boronic Acids / therapeutic use. Bortezomib. Drug Therapy, Combination. Humans. Immunosuppressive Agents / therapeutic use. Melphalan / therapeutic use. Myeloablative Agonists / therapeutic use. Neoplasm Staging. Prednisone / therapeutic use. Protease Inhibitors / therapeutic use. Pyrazines / therapeutic use. Survival Rate

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20031467.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Immunosuppressive Agents; 0 / Myeloablative Agonists; 0 / Protease Inhibitors; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  • [Number-of-references] 60
  •  go-up   go-down


10. Okacha N, Chrif E, Brahim E, Ali A, Abderrahman E, Gazzaz M, Adil B, Bouchaib K, Mohamed B: Extraosseous epidural multiple myeloma presenting with thoracic spine compression. Joint Bone Spine; 2008 Jan;75(1):70-2
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraosseous epidural multiple myeloma presenting with thoracic spine compression.
  • Multiple myeloma is a hematopoetic disorder and multicentric disease, with the most common localisation being the spine.
  • Microscopic examination and immunohistochemical studies confirmed the diagnosis of multiple myeloma of kappa subtype.
  • The patient was subsequently started on steroids and chemotherapy for myeloma.
  • [MeSH-major] Multiple Myeloma / complications. Multiple Myeloma / diagnosis. Spinal Cord Compression / etiology
  • [MeSH-minor] Humans. Immunoglobulin G. Immunohistochemistry. Laminectomy. Magnetic Resonance Imaging. Male. Middle Aged. Spinal Neoplasms / diagnosis. Spinal Neoplasms / metabolism. Spinal Neoplasms / pathology. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905632.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


11. Sellam J, Costedoat-Chalumeau N, Amoura Z, Aymard G, Choquet S, Trad S, Vignes BL, Hulot JS, Berenbaum F, Lechat P, Cacoub P, Ankri A, Mariette X, Leblond V, Piette JC: Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis. Joint Bone Spine; 2007 Oct;74(5):446-52
Hazardous Substances Data Bank. PHENINDIONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potentiation of fluindione or warfarin by dexamethasone in multiple myeloma and AL amyloidosis.
  • OBJECTIVES: Patients with primary systemic (AL) amyloidosis or multiple myeloma are frequently treated with cyclic dexamethasone (DXM) courses and often require oral anticoagulants.
  • METHODS: Nine patients with multiple myeloma (n=6) or AL amyloidosis (n=3), including 6 prospective patients, taking fluindione (n=8) or warfarin (n=1), were studied for a total of 10 cycles.
  • In controls receiving DXM without oral anticoagulants, DXM alone did not increase prothrombin time.
  • INR should therefore be monitored repeatedly during concomitant administration of these 2 drugs to allow individual adaptation of oral anticoagulant doses.
  • [MeSH-major] Amyloidosis / drug therapy. Anticoagulants / therapeutic use. Dexamethasone / therapeutic use. Multiple Myeloma / drug therapy. Phenindione / analogs & derivatives. Warfarin / therapeutic use
  • [MeSH-minor] Aged. Blood Coagulation. Creatinine / metabolism. Drug Synergism. Female. Glucocorticoids / therapeutic use. Humans. International Normalized Ratio. Male. Middle Aged. Patient Selection. Prothrombin Time

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17692552.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Glucocorticoids; 5M7Y6274ZE / Phenindione; 5Q7ZVV76EI / Warfarin; 7S5I7G3JQL / Dexamethasone; AYI8EX34EU / Creatinine; EQ35YMS20Q / fluindione
  •  go-up   go-down


12. Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, Ikeda Y, Japanese Society of Hematology, Japanese Society of Clinical Hematology: [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology]. Rinsho Ketsueki; 2006 Dec;47(12):1521-7
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology].
  • Bortezomib is a proteasome inhibitor that can be effective in the treatment of refractory and relapsed multiple myeloma.
  • Recently, severe pulmonary complications associated with bortezomib therapy have been reported in Japan.
  • Because bortezomib has not yet been approved for general use in Japan and is imported by attending physicians on the request of patients, The Japanese Society of Hematology and The Japanese Society of Clinical Hematology sent urgent questionnaires to the councilors of both societies in order to explore the situation and details of pulmonary complications associated with bortezomib therapy.
  • Of the 7 patients, 6 had a prior history of stem cell transplantation (SCT), whereas only 14 of 39 patients without lung injury had received SCT treatment (p = 0.033 by Fischer's exact test).
  • Clinicians should be aware of the possibility of severe pulmonary complications associated with bortezomib therapy.
  • [MeSH-major] Boronic Acids / adverse effects. Hematology. Lung Diseases / chemically induced. Lung Diseases / epidemiology. Multiple Myeloma / drug therapy. Protease Inhibitors / adverse effects. Pyrazines / adverse effects. Societies, Medical. Surveys and Questionnaires
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Aged, 80 and over. Bortezomib. Female. Humans. Japan / epidemiology. Male. Middle Aged. Multivariate Analysis. Recurrence. Risk Factors. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233470.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


13. Gotoh A, Ohyashiki K, Oshimi K, Usui N, Hotta T, Dan K, Ikeda Y: Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol; 2006 Dec;84(5):406-12
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology.
  • Bortezomib is a proteasome inhibitor that can be effective in the treatment of refractory and relapsed multiple myeloma.
  • Recently, severe pulmonary complications associated with bortezomib therapy have been reported in Japan.
  • Because bortezomib has not yet been approved for general use in Japan and is imported by attending physicians on the request of patients, The Japanese Society of Hematology and The Japanese Society of Clinical Hematology sent urgent questionnaires to the councilors of both societies to explore the situation and the details of pulmonary complications associated with bortezomib therapy.
  • Of the 7 patients, 6 had a prior history of stem cell transplantation (SCT), whereas only 14 of 39 patients without lung injury had received SCT treatment (P = .033, Fisher exact test).
  • Clinicians should be aware of the possibility of severe pulmonary complications associated with bortezomib therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Boronic Acids / adverse effects. Lung Diseases / chemically induced. Multiple Myeloma / complications. Pyrazines / adverse effects
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Bortezomib. Drug Approval. Female. Hematology. Humans. Japan. Lung Injury. Male. Societies, Medical. Stem Cell Transplantation / adverse effects. Stem Cell Transplantation / mortality. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Saf. 2005;28(2):103-13 [15691221.001]
  • [Cites] Intern Med. 2004 Dec;43(12):1201-4 [15645660.001]
  • [Cites] Curr Med Res Opin. 2006 Mar;22(3):561-73 [16574039.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):776-83 [15953004.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):388-92 [16489637.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3954-64 [15217925.001]
  • [Cites] J Rheumatol. 1996 Jul;23 (7):1282-5 [8823707.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):755-62 [15953001.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Blood. 2006 May 1;107(9):3492-4 [16410442.001]
  • [Cites] Eur Respir J Suppl. 2001 Sep;32:17s-29s [11816821.001]
  • [Cites] J Clin Invest. 2004 Sep;114(5):669-78 [15343385.001]
  • [Cites] Free Radic Biol Med. 2004 Nov 15;37(10):1670-9 [15477018.001]
  • [Cites] J Immunol. 2006 Apr 15;176(8):4995-5005 [16585596.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:465-76 [15822185.001]
  • (PMID = 17189220.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


14. Roux S, Mariette X: Hematological malignancies and the bone (myeloma excluded). Joint Bone Spine; 2000;67(4):264-71
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematological malignancies and the bone (myeloma excluded).
  • The treatment of hematologic malignancies presenting with bone lesions and/or hypercalcemia is similar to the treatment of the systemic disease.
  • In primary lymphomas of bone presenting with an isolated bone lesion, local treatment with radiation therapy and/or surgical ablation is required, and adjuvant chemotherapy may improve the prognosis of these located lymphomas.
  • Glucocorticoid therapy and bisphosphonates are effective in treating associated hypercalcemia.
  • Except for myeloma and ATL, the underlying mechanisms responsible for bone involvement in hematologic malignancies remain poorly understood.
  • [MeSH-major] Bone Neoplasms / pathology. Hematologic Neoplasms / pathology. Multiple Myeloma / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10963072.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 0 / Proteins
  • [Number-of-references] 51
  •  go-up   go-down


15. Goranova-Marinova VS, Pechalova-Petrova PF, Goranov SG: Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma. Folia Med (Plovdiv); 2009 Oct-Dec;51(4):53-7
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma.
  • ONJ has been mostly reported in patients with malignancies--mainly in multiple myeloma (MM) patients, followed by patients with bone metastases from breast and prostatic cancer.
  • The view that is supported by a growing body of researchers in the discussion on the etiopathogenetic relationship between ONJ and BPs is that ONJ seems to be a class-specific side effect rather than a result of the use of a specific drug.
  • The major risk factor for development of ONJ is not the BP type, but the time of their administration and accumulation in the bone structures.
  • The immunosuppressive effects of chemo- and radiotherapy, the impaired bone remodeling resulting from corticoid therapy, the antiangiogenetic properties of thalidomide slow down the reparative processes in the oral cavity and appear as a predisposing factor for the development of ONJ.
  • Possibilities for successful treatment are limited; conservative approaches and least surgery, if larger areas are involved, are recommended.
  • We present a 66-year-old man with multiple myeloma, IgG, BJ(k), II A KC (after Durie and Salmon staging system).
  • ONJ was diagnosed one year after the disease onset, during which the patient received chemotherapy and was administered concurrently 14 cycles of BPs (pamidronate/zolendronate).
  • The diagnosis was based on clinical, radiologic and histological evidence.
  • Surgical removal of the necrotic sequesters and antibiotic treatment produced a clinical improvement.
  • This rare, refractory complication requires the joint efforts of hematologists, oncologists, and maxillofacial surgeons to diagnose, manage prophylactically and treat.
  • [MeSH-major] Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Multiple Myeloma / complications. Osteonecrosis / chemically induced
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Bone Density Conservation Agents / adverse effects. Bone Density Conservation Agents / therapeutic use. Debridement / methods. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Osteolysis / drug therapy


16. Zwolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, Fisher J, Cheng EY: Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am; 2010 Jan;92(1):162-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines.
  • BACKGROUND: Local recurrence with subsequent osteolysis is a problem after intralesional curettage of giant cell tumor of bone, myeloma, and metastatic carcinoma.
  • The bisphosphonate zoledronic acid (zoledronate) has been shown to reduce osteoclast activity, and its local administration is a potentially attractive therapy, especially for the osteoclast-rich giant cell tumor.
  • The cytotoxic effects of the dissolved zoledronic acid on cultures of multiple myeloma, giant cell tumor, and renal cell carcinoma cells were tested with use of the MTT assay (tetrazolium [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] dye) and analyzed according to the zoledronic acid concentration and the elapsed time.
  • The proliferation assay (MTT) showed zoledronic acid to have significant cytotoxicity in cultures of stromal giant cell tumor, multiple myeloma, and renal cell carcinoma cells.
  • Renal cell carcinoma from bone (RBM1-IT4) and stromal giant cell tumor of bone were more susceptible to zoledronic acid than was multiple myeloma.
  • Zoledronic acid is released from bone cement, remains biologically active despite the polymerization of cement, and inhibits the in vitro growth of cell lines from giant cell tumor of bone, myeloma, and renal cell carcinoma.
  • [MeSH-minor] Bone Cements / adverse effects. Bone Cements / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Humans

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048108.001).
  • [ISSN] 1535-1386
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Cements; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


17. Robertson LP, Hutton CW, Freeman S, Hamon MD, Newman P: A rapidly destructive amyloid arthropathy associated with myeloma. J Clin Rheumatol; 2000 Jun;6(3):142-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rapidly destructive amyloid arthropathy associated with myeloma.
  • Amyloid arthropathy is a known complication of multiple myeloma.
  • However, radiologically it can produce bone cysts, but it is said to be distinguished from RA by preservation or even widening of the joint space.
  • We describe a 53-year-old man with myeloma who developed a rapidly destructive rare form of amyloid arthropathy within months of his hematologic diagnosis.
  • The myeloma was aggressive and only partially responsive to treatment; this may have influenced the severity of the joint disease.
  • The arthritis had minimal improvement with the chemotherapy.
  • Two other unusual features were an unexplained inflammatory arthritis of an elbow with associated soft tissue calcification.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19078462.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Amine B, Benbouazza K, Harzy T, Rahmouni R, Guedira N, Lazrak N, Hajjaj-Hassouni N: IgD kappa myeloma: a new case. Joint Bone Spine; 2004 Jul;71(4):331-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgD kappa myeloma: a new case.
  • IgD myeloma, which is particularly severe, accounts for only 1-3% of all myeloma cases, and the kappa subtype contributes only 10-30% of IgD myelomas.
  • Radiographs disclosed multiple punched-out lesions with no evidence of spinal cord compression.
  • Symptomatic treatment was given to correct the hypercalcemia, and combination chemotherapy was started.
  • DISCUSSION: IgD kappa myeloma is a severe variant of myeloma often associated with extraosseous lesions, renal failure, and amyloidosis.
  • The monoclonal component is absent or faint by serum protein electrophoresis, making the diagnosis difficult.
  • [MeSH-major] Immunoglobulin D. Immunoglobulin kappa-Chains. Multiple Myeloma / immunology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chlorambucil / administration & dosage. Humans. Hypercalcemia / etiology. Hypercalcemia / pathology. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Renal Insufficiency / etiology. Renal Insufficiency / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15288860.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Immunoglobulin kappa-Chains; 18D0SL7309 / Chlorambucil; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; MCP protocol
  •  go-up   go-down


19. Kast RE: Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities--the role of bupropion. Leuk Res; 2005 Dec;29(12):1459-63
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities--the role of bupropion.
  • Etanercept is a commercially available pharmaceutical protein approved for treatment of rheumatoid arthritis, RA.
  • Etanercept has a good safety record and is of benefit in lowering pain, inflammation, and joint destruction in RA.
  • Malignant myeloma, MM, is a malignant clonal expansion of a post-germinal center B lymphocyte.
  • [MeSH-major] Immunoglobulin G / pharmacology. Multiple Myeloma / drug therapy. Tumor Necrosis Factor-alpha / drug effects
  • [MeSH-minor] Bupropion / pharmacology. Etanercept. Humans. Receptors, Tumor Necrosis Factor. Receptors, Tumor Necrosis Factor, Type I / drug effects. Receptors, Tumor Necrosis Factor, Type II / drug effects. Up-Regulation / drug effects

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. Bupropion .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964626.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha; 01ZG3TPX31 / Bupropion; OP401G7OJC / Etanercept
  • [Number-of-references] 39
  •  go-up   go-down


20. Hasegawa M, Kondo F, Yamamoto K, Murakami K, Tomita M, Nabeshima K, Nakai S, Kato M, Ohashi A, Arai J, Hiki Y, Ishii J, Emi N, Sugiyama S, Yuzawa Y: Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy. Ther Apher Dial; 2010 Oct;14(5):451-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
  • Aggressive removal of circulating free light chains (FLC) by blood purification accompanied by chemotherapy is a promising approach for the treatment of acute renal failure due to myeloma cast nephropathy.
  • Plasma exchange has been performed to remove serum FLC; in order to examine an alternative strategy we performed hemodiafiltration using protein-leaking dialyzers for the treatment of dialysis-dependent acute renal failure due to myeloma cast nephropathy.
  • In the first case with κ-light chain cast nephropathy, the pre-treatment serum creatinine was 9.65 mg/dL, and the serum κ-FLC was 27100 mg/L.
  • Chemotherapy was started with high-dose dexamethasone and then switched to bortezomib plus dexamethasone.
  • In the second case with λ-light chain cast nephropathy, the pre-treatment serum creatinine was 4.14 mg/dL, and the serum λ-FLC was 4140 mg/L.
  • The combination of an intense blood purification regimen and bortezomib plus dexamethasone therapy appears to be an efficient approach to renal recovery.
  • [MeSH-major] Acute Kidney Injury / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemodiafiltration / methods. Plasma Exchange / methods
  • [MeSH-minor] Aged. Boronic Acids / administration & dosage. Bortezomib. Combined Modality Therapy. Dexamethasone / administration & dosage. Drug Therapy, Combination. Female. Humans. Immunoglobulin Light Chains / blood. Male. Middle Aged. Multiple Myeloma / complications. Pyrazines / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21175542.001).
  • [ISSN] 1744-9987
  • [Journal-full-title] Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • [ISO-abbreviation] Ther Apher Dial
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Immunoglobulin Light Chains; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


21. Camacho M, Guis S, Mattei JP, Costello R, Roudier J: Three-year outcome in a patient with Staphylococcus lugdunensis discitis. Joint Bone Spine; 2002 Jan;69(1):85-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The few reported cases of bone and joint infection by Staphylococcus lugdunensis indicate that the clinical manifestations are severe, the diagnosis elusive, and the treatment difficult.
  • We report a case of lumbar discitis caused by Staphylococcus lugdunensis in a 67-year-old man receiving chemotherapy for stage III IgA lambda multiple myeloma.
  • Treatment was with ofloxacin and pristinamycin for 1 year.
  • Although he started to improve only 5 months after treatment initiation, the outcome was favorable.
  • Follow-up at the time of this writing is 3 years.
  • [MeSH-minor] Aged. Anti-Bacterial Agents / therapeutic use. Anti-Infective Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunocompromised Host. Male. Microbial Sensitivity Tests. Multiple Myeloma / drug therapy. Multiple Myeloma / immunology. Ofloxacin / therapeutic use. Pristinamycin / therapeutic use. Staphylococcus / isolation & purification

  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. Ofloxacin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11858365.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Pristinamycin; A4P49JAZ9H / Ofloxacin
  •  go-up   go-down


22. Clézardin P, Gligorov J, Delmas P: Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine; 2000 Jan;67(1):22-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis.
  • Malignant osteolysis is a common complication of many cancers, most notably breast cancer, prostate cancer, and multiple myeloma.
  • It follows that pharmacological agents capable of inhibiting osteoclast activity, including bisphosphonates, are likely to be useful in the treatment of malignant osteolysis.
  • Many clinical trials have found bisphophonates to be effective in the treatment of complications due to malignant osteolysis.
  • Based on these studies, bisphosphonates are now indicated to treat hypercalcemia and to prevent skeletal complications of metastatic breast cancer and myeloma, in a dosage of 1600 mg.d orally for clodronate or 90 mg every four weeks intravenously for pamidronate.
  • Recent clinical trials found that prophylactic bisphosphonates therapy in patients with nonmetastasic breast cancer decreased the incidence of bone metastases, thus supporting a direct effect of biphosphonates on tumor cells.
  • Nevertheless, biphosphonates now have an undisputed place in the therapeutic armamentarium for cancer.
  • [MeSH-major] Bone Neoplasms / drug therapy. Diphosphonates / pharmacology. Diphosphonates / therapeutic use. Multiple Myeloma / drug therapy. Osteoclasts / drug effects. Osteolysis / drug therapy
  • [MeSH-minor] Animals. Humans. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10773965.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 68
  •  go-up   go-down


23. Gisserot O, Landais C, Cremades S, Terrier JP, Leyral G, Bernard P, de Jauréguiberry JP: Amyloid arthropathy and Waldenström macroglobulinemia. Joint Bone Spine; 2006 Jul;73(4):456-8
MedlinePlus Health Information. consumer health - Joint Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AL amyloidosis complicating multiple myeloma is a less common cause.
  • A synovial membrane biopsy established the diagnosis.
  • Chemotherapy was effective in alleviating the joint manifestations.
  • Joint symptoms in patients with monoclonal gammopathies, including those characterized by IgM secretion, should suggest amyloid arthropathy.
  • Treatment of the blood disease may improve the joint symptoms.
  • [MeSH-major] Amyloidosis / complications. Joint Diseases / complications. Waldenstrom Macroglobulinemia / complications
  • [MeSH-minor] Aged. Arthroscopy. Biopsy. Diagnosis, Differential. Disease Progression. Humans. Male

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16087379.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Devogelaer JP: Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol; 2000 Jul;12(4):331-5
MedlinePlus Health Information. consumer health - Bone Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of bone diseases with bisphosphonates, excluding osteoporosis.
  • The main biologic action of bisphosphonates consists of the inhibition of osteoclastic bone resorption, and, at least, for the drugs introduced after etidronate, without any significant inhibition of bone mineralization.
  • Potentially crippling conditions such as symptomatic Paget disease of bone remain a major therapeutic challenge for bisphosphonates, but the prevention of the major complications such as sarcoma has still to be proven.
  • The availability of more potent bisphosphonates, less toxic for bones, has certainly widened the therapeutic interventions to asymptomatic patients, bearing in mind the various potential troublesome complications.
  • Fibrous dysplasia resembles, in certain aspects, Paget disease; it is therefore not surprising that bisphosphonate therapy has been proposed in this indication.
  • For those with a bone metastatic propensity or malignant hematologic condition, such as multiple myeloma, the most recent generation of more potent bisphosphonates may bring more comfort to crippled patients and even, hopefully, have a direct antitumoral activity, if used synergistically with the armamentarium already available to the clinician.
  • In the future, they might be used in the prevention of erosions in rheumatoid arthritis and of loosening of joint prostheses, as well as possibly in osteoarthritis.
  • [MeSH-major] Bone Diseases / drug therapy. Diphosphonates / therapeutic use
  • [MeSH-minor] Abnormalities, Drug-Induced. Adult. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Breast Neoplasms / secondary. Child. Female. Fibrous Dysplasia of Bone / drug therapy. Humans. Male. Multiple Myeloma / drug therapy. Osteitis Deformans / drug therapy. Osteogenesis Imperfecta / drug therapy. Osteoporosis / drug therapy

  • Genetic Alliance. consumer health - Osteoporosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10910187.001).
  • [ISSN] 1040-8711
  • [Journal-full-title] Current opinion in rheumatology
  • [ISO-abbreviation] Curr Opin Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Diphosphonates
  • [Number-of-references] 30
  •  go-up   go-down


25. Vieillard MH, Maes JM, Penel G, Facon T, Magro L, Bonneterre J, Cortet B: Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. Joint Bone Spine; 2008 Jan;75(1):34-40
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
  • Intravenous amino-bisphosphonate therapy was given for metastatic bone disease from breast cancer in 7 patients and multiple myeloma in 5 patients; the remaining patient was on oral alendronate for osteoporosis.
  • Mean treatment duration was 24 months.
  • Amino-bisphosphonate therapy was discontinued in all 13 patients.
  • We suggest a classification scheme for the clinical and computed-tomography patterns seen in our patients.
  • CONCLUSION: Jaw osteonecrosis is a severe complication of amino-bisphosphonate therapy.
  • In addition to the application of published guidelines, we propose discontinuing bisphosphonate therapy whenever possible.
  • We are evaluating our classification scheme to identify early diagnostic criteria and/or clinical and computed-tomography outcome criteria that would improve the management of patients with jaw osteonecrosis.
  • [MeSH-minor] Bone Density Conservation Agents / adverse effects. Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Female. Humans. Imidazoles / adverse effects. Imidazoles / therapeutic use. Male. Middle Aged. Multiple Myeloma / drug therapy. Osteoporosis / drug therapy. Prospective Studies

  • Genetic Alliance. consumer health - Osteonecrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17981488.001).
  • [ISSN] 1778-7254
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; OYY3447OMC / pamidronate
  •  go-up   go-down


26. Razaq M, Balicas M, Mankan N: Use of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairment. Am J Ther; 2007 Jul-Aug;14(4):414-6
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • First, the compromised ability to perceive pain because of loss of sensory neurons and other comorbid conditions such as dementia and degenerative joint diseases make the assessment of severity source and localization of pain very difficult.
  • [MeSH-major] Analgesics, Opioid / therapeutic use. Back Pain / drug therapy. Hydromorphone / therapeutic use. Morphine / therapeutic use
  • [MeSH-minor] Aged. Hepatic Insufficiency / complications. Humans. Male. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Renal Insufficiency / complications

  • MedlinePlus Health Information. consumer health - Back Pain.
  • Hazardous Substances Data Bank. HYDROMORPHONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667220.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine; Q812464R06 / Hydromorphone
  •  go-up   go-down


27. Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G: Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. BioDrugs; 2004;18(4):269-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are indicated in non-neoplastic diseases including osteoporosis, corticosteroid-induced bone loss, Paget disease, and in cancer-related diseases such as neoplastic hypercalcemia, multiple myeloma and bone metastases secondary to breast and prostate cancer.
  • This activity suggests the use of non-aminobisphosphonates in several inflammatory diseases characterized by macrophage-mediated production of acute-phase cytokines, as prevention of erosions in rheumatoid arthritis, and of loosening of joint prostheses, as well as possibly in osteoarthritis, ankylosing spondylitis, myelofibrosis, and hypertrophic pulmonary osteoarthropathy.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Diphosphonates / therapeutic use. Inflammation / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Clinical Trials as Topic. Cytokines / blood. Cytokines / drug effects. Humans. Structure-Activity Relationship

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15244502.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cytokines; 0 / Diphosphonates
  • [Number-of-references] 90
  •  go-up   go-down


28. Brun J: Proteasome inhibition as a novel therapy in treating rheumatoid arthritis. Med Hypotheses; 2008;71(1):65-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteasome inhibition as a novel therapy in treating rheumatoid arthritis.
  • Rheumatoid arthritis (RA) is an erosive joint disease affecting about 1% of the population.
  • The joint destruction is primarily mediated by special cells called fibroblast-like synoviocytes (FLS), which undergo an expansion forming a pannus that destroys the joint.
  • Therefore, the FLS remain intact, joint destruction proceeds, patients relapse and eventually become resistant to all forms of therapy.
  • To date, surgical removal of the pannus remains the only option to help delay further joint destruction.
  • Therefore, we believe the future should hold a less invasive approach using a class of novel drugs called proteasome inhibitors to attenuate the growth of the FLS.
  • PS-341 has been shown to induce apoptosis in many cancer cell lines and has lead to successful outcomes in phase II and III clinical trials of multiple myeloma.
  • Moreover, PS-341 has been shown to sensitize a variety of cell lines to chemotherapeutic drugs, some of which are used as conventional therapy in RA.
  • We hypothesize that PS-341 alone and/or in combination with conventional RA therapies could induce apoptosis in FLS in vitro and in vivo thereby treating the pannus.
  • Overall, the purpose of our hypothesis is to suggest a realistic and alternative treatment for patients with refractory and non-refractory arthritic disease.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Protease Inhibitors / therapeutic use. Proteasome Inhibitors
  • [MeSH-minor] Animals. Antirheumatic Agents / therapeutic use. Apoptosis / drug effects. Boronic Acids / therapeutic use. Bortezomib. Cell Proliferation / drug effects. Humans. Models, Biological. Pyrazines / therapeutic use. Synovial Membrane / drug effects. Synovial Membrane / enzymology. Synovial Membrane / pathology

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Med Hypotheses. 2008 Nov;71(5):818 [18650027.001]
  • (PMID = 18424014.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


29. Ficarra G, Beninati F: Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects. Head Neck Pathol; 2007 Dec;1(2):132-40
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly observed in patients with multiple myeloma and bone metastasis from solid tumors receiving iv bisphosphonate therapy.
  • The mandible is more commonly affected than the maxilla (2:1 ratio), and 60-70% of cases are preceded by a dental surgical procedure.
  • The signs and symptoms that may occur before the appearance of clinical evident osteonecrosis include changes in the health of periodontal tissues, non-healing mucosal ulcers, loose teeth and unexplained soft-tissue infection.
  • Although the definitive role of bisphosphonates remains to be elucidated, the inhibition of physiologic bone remodeling and angiogenesis by these potent drugs impairs the regenerative capacity of the bone causing the development of BRONJ.
  • The significant benefits that bisphosphonates offer to patients clearly surpass the risk of potential side effects; however, any patient for whom prolonged bisphosphonate therapy is indicated, should be provided with preventive dental care in order to minimize the risk of developing this severe condition.
  • [MeSH-minor] Administration, Oral. Humans. Imidazoles / administration & dosage. Imidazoles / adverse effects. Injections, Intravenous. Mandible / drug effects. Mandible / pathology. Retrospective Studies

  • Genetic Alliance. consumer health - Osteonecrosis.
  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Dis. 2005 Nov;11(6):365-9 [16269027.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Jan;4(1):42-55 [17183355.001]
  • [Cites] Br J Oral Maxillofac Surg. 2007 Dec;45(8):628-32 [17524535.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 [12966493.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4253-4 [14615459.001]
  • [Cites] J Oral Maxillofac Surg. 2004 May;62(5):527-34 [15122554.001]
  • [Cites] Lancet. 2004 Jul 24-30;364(9431):369-79 [15276398.001]
  • [Cites] Am J Med. 2004 Sep 15;117(6):440-1 [15380503.001]
  • [Cites] Br Dent J. 1972 Sep;133(5):203-6 [4507255.001]
  • [Cites] Head Neck Surg. 1982 Jan-Feb;4(3):251-3 [6896046.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jun;83(6):657-62 [9195618.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Jul;84(1):16-21 [9247943.001]
  • [Cites] J Oral Pathol Med. 2005 Feb;34(2):120-3 [15641993.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):738 [15755276.001]
  • [Cites] J Oral Maxillofac Surg. 2005 May;63(5):682-9 [15883944.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):83-93 [15929121.001]
  • [Cites] Urology. 2005 Sep;66(3):658 [16140106.001]
  • [Cites] J Oral Pathol Med. 2005 Nov;34(10):613-7 [16202082.001]
  • [Cites] J Clin Periodontol. 2005 Nov;32(11):1123-8 [16212571.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Nov;63(11):1567-75 [16243172.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8580-7 [16314620.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):114 [16371027.001]
  • [Cites] J Oral Pathol Med. 2006 Mar;35(3):155-60 [16454811.001]
  • [Cites] Joint Bone Spine. 2006 Jan;73(1):7-9 [16386936.001]
  • [Cites] Laryngoscope. 2006 Jan;116(1):115-20 [16481822.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):945-52 [16484704.001]
  • [Cites] Med Oncol. 2006;23(1):51-6 [16645229.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):753-61 [16702591.001]
  • [Cites] Lancet Oncol. 2006 Jun;7(6):508-14 [16750501.001]
  • [Cites] J Orthop Res. 2006 Jul;24(7):1342-8 [16718682.001]
  • [Cites] Clin Microbiol Infect. 2006 Aug;12(8):776-81 [16842573.001]
  • [Cites] J Am Dent Assoc. 2006 Aug;137(8):1115-9; quiz 1169-70 [16873327.001]
  • [Cites] Br J Haematol. 2006 Sep;134(6):620-3 [16889620.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Mar;65(3):369-76 [17307580.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Mar;65(3):562-5 [17307610.001]
  • [Cites] Ann Pharmacother. 2007 Feb;41(2):276-84 [17299010.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):1172-5 [17179196.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(5):852-8 [17258449.001]
  • [Cites] Bone. 2007 Apr;40(4):828-34 [17236837.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):148-52 [17336086.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):780-6 [17223592.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):315-22 [17545793.001]
  • [Cites] J Oral Pathol Med. 2007 Jul;36(6):319-28 [17559492.001]
  • [Cites] Acta Oncol. 2007;46(5):581-91 [17562434.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Jun-Jul;28(6):1139-45 [17569974.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1321-7 [17577496.001]
  • [Cites] J Oral Maxillofac Surg. 2007 Jul;65(7):1328-31 [17577497.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3537-40 [11061497.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1545-8 [17410188.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):69-71 [17598839.001]
  • [Cites] J Am Dent Assoc. 2007 Jul;138(7):971-7 [17606496.001]
  • [Cites] J Natl Cancer Inst. 2007 Jul 4;99(13):1016-24 [17596574.001]
  • [Cites] Semin Arthritis Rheum. 2007 Aug;37(1):1-12 [17303219.001]
  • [Cites] Bone. 2007 Sep;41(3):318-20 [17572168.001]
  • [Cites] Osteoporos Int. 2007 Oct;18(10):1363-70 [17598065.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Oct;104(4):473-7 [17482847.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1104-7 [12966490.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Oct;102(4):433-41 [16997108.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1512-6 [16936182.001]
  • [Cites] J Craniofac Surg. 2006 Nov;17(6):1080-3 [17119409.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2278-81 [17135582.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):457-63 [12890844.001]
  • (PMID = 20614264.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; OYY3447OMC / pamidronate
  • [Other-IDs] NLM/ PMC2807525
  • [Keywords] NOTNLM ; Bisphosphonate / Bone metastasis / Cancer / Jaws / Osteomyelitis / Osteonecrosis / Osteoporosis / Pamidronate / Review / Zoledronic acid
  •  go-up   go-down


30. Merino P, Arribi A, Gestoso I, Picazo J, Gimeno L, Del Potro E: Linezolid treatment of a prosthetic joint infection with Staphylococcus lugdunensis in a patient with multiple myeloma. Int J Antimicrob Agents; 2010 Feb;35(2):203-4
Hazardous Substances Data Bank. LINEZOLID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linezolid treatment of a prosthetic joint infection with Staphylococcus lugdunensis in a patient with multiple myeloma.
  • [MeSH-major] Acetamides / therapeutic use. Anti-Bacterial Agents / therapeutic use. Arthritis / drug therapy. Multiple Myeloma / complications. Oxazolidinones / therapeutic use. Prosthesis-Related Infections / drug therapy. Staphylococcal Infections / drug therapy
  • [MeSH-minor] Humans. Linezolid. Male. Middle Aged. Treatment Outcome


31. Lin RJ, Curran JJ, Zimmerman TM, Song J, Niewold TB, Sweiss NJ: Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma. J Clin Rheumatol; 2010 Mar;16(2):90-1
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cryoglobulinemia / drug therapy. Multiple Myeloma / complications. Spondylarthropathies / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. HLA-B27 Antigen / analysis. Humans. Lumbar Vertebrae. Male. Sacroiliac Joint

  • Genetic Alliance. consumer health - Cryoglobulinemia.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Res Ther. 2004;6 Suppl 2:S36-43 [15228620.001]
  • [Cites] Eur J Dermatol. 2004 May-Jun;14(3):186-9 [15246947.001]
  • [Cites] Br J Rheumatol. 1996 Mar;35(3):241-3 [8620298.001]
  • [Cites] Ann Hematol. 2005 Sep;84(9):609-13 [15906029.001]
  • [Cites] J Clin Rheumatol. 2009 Aug;15(5):238-40 [19590446.001]
  • [Cites] Blood Rev. 2007 Jul;21(4):183-200 [17289231.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2962-72 [18332230.001]
  • [Cites] Leuk Lymphoma. 2008 Jul;49(7):1238-45 [18452080.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):972-4 [16924045.001]
  • (PMID = 20130475.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K08 AI083790; United States / NIAID NIH HHS / AI / K08 AI083790-03; United States / NIAID NIH HHS / AI / L30 AI071651; United States / NIAID NIH HHS / AI / L30 AI071651-03
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / HLA-B27 Antigen; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ NIHMS364112; NLM/ PMC3319139
  •  go-up   go-down


32. Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I, Benner A, Glasmacher A, Schmidt-Wolf IG, Martin H, Hoelzer D, Ho AD, Lokhorst HM, HOVON, GMMG: Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol; 2003 Oct;82(10):654-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / drug therapy. Thalidomide / administration & dosage
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Middle Aged. Prospective Studies. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12845480.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin
  •  go-up   go-down






Advertisement